Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Antibody entities : Bristol-myers squibb company save search
Global Antibody Therapeutic Industry Research 2023-2024 & 2033: Exploring the Expanding Role in Managing Cancer, Autoimmune Disorders, and Infectious Diseases
Published: 2024-03-28 (Crawled : 15:30) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: 0.02%
H: 0.51%
C: -0.3%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.28%
H: 1.71%
C: -0.3%
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
AMGN | $266.895 1.58% 950K
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
antibody research global
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Published: 2023-09-18 (Crawled : 06:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
drug antibody cancer agreement
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Published: 2023-09-17 (Crawled : 00:00) - prnewswire.com
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
drug antibody cancer agreement
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma
Published: 2022-07-22 (Crawled : 12:20) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.41%
treatment melanoma antibody chmp approval positive nivolumab
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -10.51%
H: 0.0%
C: 0.0%
phase 1 results antibody
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
Published: 2021-10-01 (Crawled : 12:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
treatment europe antibody nivolumab
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.18%
H: 1.22%
C: -0.23%
food treatment antibody drug nivolumab
Global Antibody Market Expected to Reach USD 318,482.1 Million by 2027, With a CAGR Of 10.1% | Growth Market Reports
Published: 2021-07-23 (Crawled : 14:00) - prnewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.06%
H: 0.78%
C: 0.5%
BIO | News | $277.33 -1.31% 110K
|
Health Technology
|
| O: 0.22%
H: 1.29%
C: 0.89%
BDX | $235.01 0.8% 330K
|
Health Technology
|
| O: 0.26%
H: 0.63%
C: 0.43%
A | $133.2 0.57% 390K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: 0.0%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
antibody growth
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207
Published: 2021-07-19 (Crawled : 12:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -0.96%
H: 0.69%
C: -0.66%
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -3.29%
H: 1.48%
C: -0.74%
phase 1 expansion antibody
Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
Published: 2021-06-17 (Crawled : 01:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.16%
H: 0.21%
C: -0.39%
collaboration antibody drug
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN | $5.62 13.08% 510K
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license milestone
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Published: 2021-05-18 (Crawled : 12:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN | $5.62 13.08% 510K
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab)
Published: 2021-03-25 (Crawled : 12:15) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: -0.33%
antibody trial nivolumab
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Published: 2021-02-03 (Crawled : 13:00) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: -0.11%
H: 0.54%
C: -1.34%
covid treatment antibody license sars-cov-2
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
CHRO | $1.53 24.9% 100K
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
INSG | $2.98 23.14% 190K
|
Electronic Technology
TPET | $0.4001 22.02% 35M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.